Company profile: Atsena Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage gene therapies and AAV delivery technologies for inherited retinal diseases: ATSN-101 for GUCY2D-associated LCA1, ATSN-201 leveraging AAV.SPR for XLRS, and ATSN-301 dual AAV vectors for MYO7A-associated USH1B; plus laterally spreading capsids for broad retinal delivery, dual-vector methods for large genes, and intravitreal capsids that evade neutralizing antibodies.
Products and services
- ATSN-101: Phase I/II gene therapy for GUCY2D-associated Leber congenital amaurosis (LCA1), developed to address inherited blindness in affected patients
- ATSN-201: AAV.SPR capsid–enabled, Phase I/II gene therapy for X-linked retinoschisis (XLRS), built to target progressive vision loss
- Laterally Spreading Capsids: AAV.SPR-based technology enabling enhanced gene delivery across large areas of the retina, including safe delivery to the fovea
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atsena Therapeutics
Prevail Therapeutics
HQ: United States
Website
- Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevail Therapeutics company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
ReNAgade Therapeutics
HQ: United States
Website
- Description: Provider of RNA therapeutic platforms, offering RNA delivery systems to target previously inaccessible cells, an RNA coding platform (with Orna Therapeutics) for reprogramming cells, proprietary gene editing technology for permanent gene correction, and an all-RNA Gene Therapy 2.0 platform enabling exon and large gene insertions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReNAgade Therapeutics company profile →
Regulus Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-based therapeutics designed to inhibit dysregulated microRNA targets for genetically based orphan diseases, particularly orphan kidney diseases. Portfolio includes RGLS8429, a next-generation anti-miR-17 in Phase 1b for autosomal dominant polycystic kidney disease (ADPKD), supported by ongoing clinical trials to evaluate efficacy and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regulus Therapeutics company profile →
Phio Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi immuno-oncology therapies leveraging the INTASYL self-delivering RNAi platform to create siRNA compounds that silence gene targets. Pipeline includes PH-762 (intratumoral PD-1 silencing for cSCC, melanoma, Merkel cell carcinoma), PH-894 (intratumoral BRD4 silencing for advanced melanoma and other cancers), and PH-762 + adoptive cell therapy with double positive CD8 Tils (IV for stage IV melanoma and solid tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phio Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atsena Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atsena Therapeutics
2.2 - Growth funds investing in similar companies to Atsena Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atsena Therapeutics
4.2 - Public trading comparable groups for Atsena Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →